Concepedia

Julius Strauss

JS

34

Publications

1.9K

Citations

20

H-Index

1974

Active since

Affiliations

National Cancer Institute(Current)

National Institutes of Health

Center for Cancer Research

Merck (Germany)

Ono Pharmaceutical (United States)

Julius Strauss is an author at National Cancer Institute specializing in medicine, pathology, and radiation oncology.

ORCID

Top concepts

Publications per year

1974–2025

34

Publications

34

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 406 citations · Full text

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Marijo Bilušić, Christopher R. Heery, Julie Collins et al. · Journal for ImmunoTherapy of Cancer · 2019 · 256 citations · Full text

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors

Julius Strauss, Christopher R. Heery, Joseph W. Kim et al. · Clinical Cancer Research · 2018 · 164 citations · Full text

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho et al. · Journal for ImmunoTherapy of Cancer · 2020 · 153 citations · Full text

Anti–PD-L1 Treatment Induced Central Diabetes Insipidus

Chen Zhao, Sri Harsha Tella, Jaydira Del Rivero et al. · The Journal of Clinical Endocrinology & Metabolism · 2017 · 102 citations · Full text

Rows per page

1–5 of 34